Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Consensus Recommendation of “Hold” by Brokerages

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has been given an average rating of “Hold” by the nine ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $34.3333.

Several brokerages recently weighed in on LKFT. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Zacks Research raised shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Morgan Stanley assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They set an “equal weight” rating and a $30.00 price target for the company. Finally, Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.4%

NASDAQ LKFT opened at $29.60 on Friday. The firm has a market cap of $1.95 billion, a P/E ratio of -20.99 and a beta of 0.25. Lakefront Biotherapeutics American Depositary Shares has a 52-week low of $26.42 and a 52-week high of $37.78. The business’s 50-day moving average price is $28.60 and its 200 day moving average price is $30.76.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.52. The company had revenue of $8.75 million for the quarter, compared to analyst estimates of $11.26 million. As a group, analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC boosted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after purchasing an additional 115,946 shares in the last quarter. Geode Capital Management LLC purchased a new stake in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $220,000. Jump Financial LLC acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $692,000. Boothbay Fund Management LLC acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $612,000. Finally, Engineers Gate Manager LP purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at about $560,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.